Evidence map›Paper›PMID 38868281›Full record

ArticleCureus2024

Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the Literature.

Shinnosuke Hiruta, Go Kaneko, Yu Miyama, Yousuke Miyasaka, Yuta Umezawa, Masayuki Hagiwara, Suguru Shirotake, Kent Kanao, Masanori Yasuda, Masafumi Oyama

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shinnosuke HirutaUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Go KanekoUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Yu MiyamaPathology, Saitama Medical University International Medical Center, Hidaka, JPN.
Yousuke MiyasakaOphthalmology, Saitama Medical University International Medical Center, Hidaka, JPN.
Yuta UmezawaUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Masayuki HagiwaraUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Suguru ShirotakeUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Kent KanaoUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.
Masanori YasudaPathology, Saitama Medical University International Medical Center, Hidaka, JPN.
Masafumi OyamaUrologic Oncology, Saitama Medical University International Medical Center, Hidaka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal metastasis originating from renal cell carcinomas (RCCs) is rare. To the best of our knowledge, 31 cases of choroidal metastasis from RCC have been reported in the English literature as of January 31, 2024. Nevertheless, physicians need to be vigilant in recognizing this condition, as its progression impacts the quality of life (QOL) of affected patients. In Case 1, a 60-year-old male with a medical history of papillary RCC experienced a deterioration in visual acuity (VA) and was diagnosed with solitary choroidal metastasis. Subsequently, multiple metastases were identified, prompting the initiation of a combination therapy regimen consisting of pembrolizumab plus axitinib. Despite treatment, progression of choroidal metastasis and a further decline in VA were observed. The patient underwent stereotactic radiotherapy and experienced complete resolution of the choroidal metastasis, accompanied by a slight improvement in VA. In Case 2, a 76-year-old man presented with a renal tumor accompanied by lung metastases. He underwent nephrectomy, and the histological diagnosis was papillary RCC. We initiated combination therapy consisting of nivolumab plus cabozantinib. The patient experienced a decrease in VA during treatment. We identified extensive fine metastases scattered throughout the bilateral choroid. We administered axitinib, but the patient experienced bilateral blindness. Given the absence of established therapy for choroidal metastasis, it is crucial to maintain flexibility in treatment selection. Local or systemic approaches should be used as deemed appropriate for each individual case.

Indexed as

choroidal metastasisimmune checkpoint inhibitorkidney papillary renal cell carcinomamolecular-targeted therapynon-clear cell renal carcinomarenal cell carcinomastereotactic radiotherapy

Identifiers

PMID38868281
PMCPMC11167576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.